Fig. 1: Purified exosome product (PEP) characterization, quantification, and delivery biodistribution.

A NanoSight nanoparticle analysis of size distribution and concentration of PEP diluted in phosphate buffered saline 1:1000 documented 6.65 × 10¹² ± 1.16 × 10¹¹. B Transmission electron microscopy of PEP. Scale = 200 nm arrow heads pointing to EVs. C Western blot probing for CD63, CD9, and Flotillin-1 in 3 separate CGMP manufactured PEP lots. D Western blot comparison of NF-κB p65 and PD-L1 levels, in 3 separate CGMP manufactured PEP lots versus adipose-derived mesenchymal stem cell conditioned media (AMSC-CM). E Atomic-force microscope comparing platelet-conditioned medium EV isolation using centrifugation versus the PEP process, scale bar embedded in the image. F Representative image from Single-particle interferometric reflectance imaging sensing (SP-IRIS) analysis for presence of surface CD41a, CD9, CD63, and CD81 tetraspanins. G Graphical representation of the SP-IRIS analysis. H Quantitation of CD9, CD63 and CD81 on a CD41a captured plate documented vast majority of PEP as CD41a/CD9 positive, with smaller representation from CD63 and background CD81. Data presented as mean ± stdev. N = 3 separate CGMP manufactured PEP lots. I Pie chart representation of the exosome tetraspanin surface marker profile of CD41a captured PEP exosomes.